The sites are ready to enroll atopic dermatitis patients into the company's multiple ascending dose study testing.
Biopharmaceutical company ASLAN Pharma is opening clinical sites in Australia and the US, the company announced via a press release.
Aslan Pharma also shared that it was ready to enroll atopic dermatitis (AD) patients into its multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004. Patients will now be recruited from four sites in Australia, three sites in the US, alongside two existing sites in Singapore.
ASLAN has recently restarted recruitment into the second cohort of the randomised, double blind, placebo-controlled study in Singapore following the lifting of government restrictions in response to COVID-19. All eight patients have now been fully recruited into the cohort and ASLAN plans to initiate recruitment into the third cohort following approval by the Data Monitoring Committee. A further eight patients will be recruited in Singapore, the US and Australia. ASLAN expects to report interim, unblinded data from all 3 dose cohorts in Q4 of this year.
ASLAN004 is a first-in-class monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of AD, such as redness and itching of the skin.
Do you know more about this story? Contact us anonymously through this link.